Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Gilead Sciences, Inc. is one of them.

Gilead Sciences, Inc. (NASDAQ:GILD), headquartered in Foster City, California, continues to lead in antiviral and oncology therapies while advancing next-generation biologics through AI integration. Under CEO Daniel O’Day, the company is focusing on precision medicine and translational science to accelerate development and global patient access.

In September 2025, Gilead Sciences, Inc. (NASDAQ:GILD) broke ground on a new 180,000-square-foot Pharmaceutical Development and Manufacturing (PDM) Technical Development Center at its Foster City campus. The AI-enabled facility features autonomous robotics, real-time digital monitoring, and advanced infrastructure designed to streamline biologics production and accelerate technology transfer. This center is part of the firm’s $32 billion U.S. investment plan through 2030, aimed at strengthening domestic manufacturing capacity, supporting high-quality jobs, and embedding artificial intelligence into operational workflows.

The facility will enhance data-driven insights and process automation for therapies, including CAR-T treatments and next-generation antivirals, reflecting a strategic trend toward AI-powered efficiency and innovation. Gilead Sciences, Inc. (NASDAQ:GILD), often cited among the best biotech stocks, is uniting discovery, development, and manufacturing under digital-first platforms to reduce time-to-market for new therapies and bolster its competitive edge.

Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030

Beyond infrastructure, Gilead Sciences, Inc. (NASDAQ:GILD) is expanding its global health impact. A partnership with PEPFAR will deliver twice-yearly administration of lenacapavir for HIV prevention, targeting up to two million people in low- and lower-middle-income countries by the end of 2025. Regulatory submissions for lenacapavir for PrEP are planned in 18 key countries, reinforcing the corporation’s commitment to broadening access to life-saving treatments.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.